Research and development

Vossensteyn Labs are best in class for developing plant derived medicines. Not only at the level of molecule treatment but also isolating, mixing, binding, solving, stabilizing and preserving the most complicated liquids, to make them fit for purpose for our high end medical compounds.


The laboratories of the University Medical Center Utrecht (UMCU) are developing a unique COVID-19 biobank, include viral isolates and nasal airway epithelial cells from patients, which will be used to quantitate in vitro characteristics related to virus-epithelium interactions, and to study correlations with mild or severe COVID-19 in patients. This will be done by assessment of viral replication and epithelial gene expression by single cell RNA sequencing. Additionally, nasal airway epithelial cell cultures will be used for large scale SARS-CoV-2 antiviral drug screening. Drugs of interests are published products and in-house FDA approved drugs (~1400 compounds), proprietary antimicrobial peptides with observed efficacy to SARS-CoV-2 pseudo-virus (Utrecht University) and various products with different modes-of-action from Vossensteyn Biomedical.

The latest news


Ontwikkeling Vostesyl stap verder

‘Er is veel meer mogelijk’ Robbert Roos Het Streekblad publiceerde in april voor het eerst een artikel over het middel Vostesyl van startup Vossensteyn Biochemicals.

Read More »

Clear COVID-19

Clinically-validated nasal airway epithelial cell models for COVID-19 high throughput drug development The current COVID-19 pandemic has a strong impact on individual health and social

Read More »